We investigate multiple aspects of monoclonal antibodies and vaccines with the aim to understand how and why these drugs work or fail so that we can design new drugs and strategies to translate into better treatments for patients.
We take a holistic approach to understand these therapeutics, from single atom resolution of how they bind their targets, to how they influence the cells of the immune system using in vitro and in vivo models. Accordingly, we have a mix of basic scientists, clinicians and next generation pre-clinical modelling experts, possessing expertise in T cell, B cell and myeloid cell biology. Our large collaborative group creates the required critical mass to enables us to study all aspects of antibody biology and immune-oncology, and allows us to deliver cutting-edge transformative science with translation into real world impact.
Our research involves close collaboration with colleagues in the Schools of Biological Sciences and Chemistry to understand the molecular detail of how antibodies interact with their targets. We also engage with the Experimental Cancer Medicine Centre, Wessex Investigational Sciences Hub laboratories and the Clinical Trials Unit to progress our therapeutics into the clinic.
We work closely with several biotech and pharma companies to progress our potential therapeutics for clinical testing; multiple members of the group also serve an advisory role to relevant companies in the field.